ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

INSY Insys Therapeutics, Inc.

0.2911
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Insys Therapeutics, Inc. NASDAQ:INSY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.2911 0.30 0.315 0 01:00:00

INSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference

27/09/2018 11:53pm

GlobeNewswire Inc.


INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more INSYS THERAPEUTICS, INC. Charts.

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will present at the upcoming 2018 Cantor Global Healthcare Conference as follows:

Date: Tuesday, Oct. 2, 2018
Time: 1:05 p.m. Eastern Time
Location: New York, N.Y.

The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the Investors section of company’s website at https://www.insysrx.com/, under Presentations & Events. Accessible at the same webpage, the presentation slides will be available during and after the conference.

About INSYS

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome, opioid addiction and overdose, and other disease areas with a significant unmet need.C 

CONTACT:Corporate CommunicationsInvestor Relations
 Joe McGrathJackie Marcus or Chris Hodges
 INSYS TherapeuticsAlpha IR Group
 480-500-3101312-445-2870
 jmcgrath@insysrx.comINSY@alpha-ir.com

 

1 Year INSYS THERAPEUTICS, INC. Chart

1 Year INSYS THERAPEUTICS, INC. Chart

1 Month INSYS THERAPEUTICS, INC. Chart

1 Month INSYS THERAPEUTICS, INC. Chart

Your Recent History

Delayed Upgrade Clock